Ticker News
$COSM News
Stored TradersLink news articles and press-release context for this ticker. Discord alerts link into these article pages when full article text is available.
Published Articles
Latest saved alerts
Cosmos Health (COSM) Signs Qatar Distribution Deal with IMC, Gets 31,000‑Unit Order
Cosmos Health announced a distribution agreement with International Medical Company (IMC) to roll out its Sky Premium Life nutraceuticals in Qatar, and IMC placed an initial purchase order for 31,000 units. IMC’s Kulud Pharmacies network (over 130 branches) will handle sales, marketing, regulatory affairs, logistics and distribution, giving Cosmos immediate nationwide retail reach as it expands into Gulf markets.
COSM signs distribution deal with Qatar's IMC; initial 31,000‑unit order for Sky Premium Life
Cosmos Health (NASDAQ: COSM) signed a distribution agreement with International Medical Company (IMC), owner of Qatar's Kulud Pharmacies, to sell its Sky Premium Life nutraceutical line in Qatar; IMC placed an initial purchase order for 31,000 units and will handle sales, regulatory, logistics and distribution. The deal gives Cosmos immediate retail access across Kulud's >130 pharmacies and supports Sky Premium Life's Gulf expansion, though the company did not disclose pricing, revenue impact or the cadence of follow-on orders.
COSM: C‑Sept PRO gains traction in Greek hospitals; annualized sales >$1.3M at ~72% gross margin
Cosmos Health (NASDAQ: COSM) said its C-Sept PRO antiseptic has accelerated adoption across major Greek public and private hospitals, with average monthly sales >$93k over six months and >$108k over the last three months, putting annualized sales above $1.3M and implying roughly $0.9M in annualized gross profit at ~72% gross margin. The company cites repeat ordering and participation in public hospital tenders as demand drivers and intends to scale the hospital antiseptics business further in Greece and eventually into other European markets using its EU GMP manufacturing platform.
Cosmos Health's Cana secures >25M-unit CMO orderbook; division positioned for >$10M/year profit
Cosmos Health (NASDAQ: COSM) says its wholly owned Cana Laboratories has secured a cumulative contract-manufacturing orderbook of more than 25 million units across multiple EU and international partners, with multi-year terms up to 10 years and orders spanning nine therapeutic categories. The company upgraded its 54,000 sq. ft. EU‑GMP/EMA‑certified Athens facility (~$5.5M capex) and added an ACG capsule-filling line; Cosmos says the CMO division is positioned to generate over $10 million in recurring annual profit at full capacity, while continuing to pursue additional contracts.
COSM subsidiary CosmoFarm reports Q2 revenue >$15M, $60M+ annualized run-rate; adds 80+ pharmacies and expands automation
CosmoFarm, the wholly owned Cosmos Health (COSM) subsidiary, reported record Q2 2026 revenue of over $15M, implying an annualized run-rate above $60M, and added more than 80 pharmacies to its distribution network. The company says it is increasing capex for robotic automation, AI-driven procurement/inventory systems and facility expansion to support higher volumes and improve unit economics.
COSM: Cosmos Health launches premium Korean collagen skincare; US DTC sales live
Cosmos Health (NASDAQ: COSM) announced entry into the global skincare market with a premium Korean-developed collagen-based line and says direct-to-consumer sales have been live in the U.S. for over a month as it plans a multi-brand rollout. The company highlights the $163B global skincare market and EU GMP-certified manufacturing via subsidiary Cana Laboratories, but disclosed no sales figures, financial guidance or expected revenue contribution from the launch.
COSM inks 5-year deal to manufacture 2.86M dermatology units for Pharmex
Cosmos Health (NASDAQ: COSM) said its Cana Laboratories subsidiary signed a five-year contract to manufacture three dermatological products for Pharmex S.A., totaling ~2.86 million units (≈572k units annually) at its EU‑GMP/EMA‑certified facility. The deal should boost utilization and recurring, higher‑margin contract manufacturing revenue, but the company disclosed no pricing or revenue guidance so near‑term financial impact is unclear.
Cosmos Health signs 5-year, 2.86M‑unit contract to manufacture 3 dermatology products for Pharmex
Cosmos Health (NASDAQ: COSM) said subsidiary Cana Laboratories agreed a five-year contract to manufacture three dermatological products for Pharmex, totaling ~2.86 million units (≈572k units/year) at its EU‑GMP/EMA‑certified facility. The deal should boost EU plant utilization and recurring, higher‑margin contract manufacturing revenue, but financial terms were not disclosed and the annual volume is modest versus large-scale pharma contracts.
COSM launches 4 U.S. 18-Series nutraceuticals targeting >$22.7M revenue and ~$17M gross profit
Cosmos Health (NASDAQ: COSM) gave a U.S. commercial update for its '18 Series' nutraceutical platform, announcing four products with company-projected annualized U.S. revenue of over $22.7M and implied gross profit of roughly $17.0M (using ~75% gross margin). The platform is early-stage (five products launched, one without a projection), selling direct-to-consumer with reported early demand and planned retail expansion; the figures are forward-looking company projections, not audited results.
Cosmos Health projects >$22.7M annual U.S. revenue from four 18‑Series nutraceuticals (~75% gross margin)
Cosmos Health (COSM) said its U.S. 18 Series platform has launched five products and four with disclosed projections are targeted to generate over $22.7M in annualized U.S. revenue and roughly $17.0M in implied gross profit (based on ~75% gross margin). The program is at an early stage with encouraging direct‑to‑consumer demand and plans to scale to additional retail channels, but the figures are forward‑looking targets rather than reported results.
Cosmos Health subsidiary wins 253,657-unit contract manufacturing orders
Cosmos Health (NASDAQ: COSM) said its Cana Laboratories unit received contract manufacturing orders from Nassington and Verisfield totaling 253,657 units for a mix of products including Gritse oral solutions, Gritse forte, Fungofort spray, Paco-4 tablets, dexamethasone oral solutions, and Foproct rectal cream. The work will be performed at Cana, which operates under EU GMP/EMA certification, representing non-dilutive manufacturing revenue and deeper partner relationships, though the release gave no pricing, delivery schedule, or estimated revenue impact.
COSM: C‑Scrub/C‑Sept hit $1.5M annualized in UK/Greece; company targets $7.4M revenue and $5.3M gross profit by 2028
Cosmos Health says its antiseptic brands C‑Scrub and C‑Sept have generated more than $1.5M in combined annualized sales across the UK and Greece and it disclosed a three‑year plan targeting $2.5M revenue in 2026, $4.2M in 2027 and $7.4M in 2028 with gross profit of about $5.3M (implied ~72% margins). The company notes established retail and hospital distribution (UK Amazon listings with ~900 ratings, Tesco, Superdrug, and Greek hospitals), plans broader EU expansion and an extension into animal healthcare, but the targets are forward‑looking and not guaranteed.
Cosmos Health (COSM) signs LOI to acquire GMP manufacturer Doc Pharma; says deal will be accretive
Cosmos Health (NASDAQ: COSM) entered a non-binding LOI to acquire Doc Pharma S.A., a GMP‑licensed ~59,000 sq ft European drug manufacturer that Cosmos says brings ~ $24M of assets, a three‑year average of ~$6.7M in annual revenue and ~$3.2M in average annual gross profit; the company says the acquisition would deepen vertical integration, expand capacity and be immediately accretive to margins and cash flow. Doc Pharma is a related‑party; the transaction requires independent director review, a fairness opinion, a PCAOB audit, shareholder approval and final due diligence, so completion and the touted benefits are not guaranteed.
COSM LOI to buy Doc Pharma — adds GMP plant and ~$24M in assets
Cosmos Health (NASDAQ: COSM) signed a non-binding LOI to acquire 100% of Doc Pharma S.A., a European GMP-certified pharmaceutical manufacturer with an ~59,000 sq ft production facility, multiple certifications (GMP/ISO/Kosher/Halal) and approvals for several Middle East markets. The company says the deal would be immediately accretive — Doc Pharma's three‑year averages are ~ $24M in assets, ~$6.7M annual revenue and ~$3.2M annual gross profit — and would deepen vertical integration, expand dosage-form capabilities, and broaden Cosmos's branded generics/OTC portfolio. The target is a related party, so the transaction requires independent committee review, a fairness opinion, a PCAOB audit, shareholder approval and final due diligence; completion is not guaranteed.
COSM gets 180-day Nasdaq extension to regain $1 bid-price compliance
Cosmos Health (NASDAQ: COSM) said Nasdaq granted an additional 180-day period, through Dec. 7, 2026, to regain compliance with the $1.00 minimum bid-price rule after Nasdaq found the company meets all other listing requirements. To cure the deficiency the stock must close at $1.00+ for 10 consecutive business days; the company says it prefers to restore compliance via business execution rather than a reverse stock split, which it would use only if necessary.
COSM: Cana inks 3-year deal to make 3.9M VASCLOR GEST progesterone pessaries for Verisfield
Cosmos Health's subsidiary Cana Laboratories signed a three-year contract manufacturing agreement with Verisfield to produce 1.3M units per year (3.9M total) of VASCLOR GEST (progesterone 400mg) vaginal pessaries for luteal phase support/assisted reproduction. The deal expands Cana's contract-manufacturing footprint into women's health using its EU GMP-certified facilities and aims to grow its high-margin manufacturing division, but the company did not disclose pricing or expected revenue so the financial impact is unclear.
COSM inks 3-year CMO deal to make 3.9M progesterone pessaries for Verisfield
Cosmos Health (NASDAQ: COSM) said subsidiary Cana Laboratories signed a three-year contract manufacturing agreement to produce 1.3M VASCLOR GEST (progesterone) 400 mg vaginal pessaries per year (3.9M units total) for luteal phase support and assisted reproduction. The deal expands Cana's EU GMP/EMA-certified contract-manufacturing footprint into women's health and is described as a higher-margin, recurring revenue stream, though the company disclosed no pricing so the financial impact is unclear.
Cosmos Health (COSM) CEO letter: record revenue, U.S. expansion active and $200M-by-2029 guidance
CEO Greg Siokas issued a shareholder letter saying Cosmos Health hit record FY2025 revenue of $65.3M and delivered its strongest Q1 2026 ($17.9M), with management forecasting >$90M in FY2026 and $200.6M revenue by 2029 (Adjusted EBITDA $44.2M). The letter highlights operational wins (GMP contract manufacturing at Cana, record CosmoFarm distribution, C‑Scrub clinical validation and veterinary launch), an active U.S. commercial rollout projecting >$20M annualized at ~75% gross margins within 12–18 months, pursuit of up to €25M EIB financing, and ~$20M of non‑core assets (including real estate) identified to unlock value.
COSM CEO letter: record revenue, U.S. expansion live and guidance to $200M revenue by 2029
Cosmos Health (NASDAQ: COSM) CEO Greg Siokas issued a shareholder letter reporting record FY2025 revenue of $65.3M and the strongest-ever Q1 2026 (Q1 revenue $17.9M, adjusted $18.4M), with FY2026 expected to exceed $90M and multi-year guidance targeting $200.6M revenue and $44.2M Adjusted EBITDA by 2029. The letter emphasizes the company’s active U.S. market entry (projected >$20M annualized U.S. revenue at ~75% gross margin within 12–18 months), pursuit of institutional R&D financing with the European Investment Bank, identification of ~$20M in non-core assets to unlock liquidity, and continued insider share purchases.
Cosmos Health unit acquires international patent application, expands nanotech product development
Cana Laboratories, Cosmos Health's wholly owned subsidiary, acquired international patent application WO2025108566A1 from Cloudpharm and is pursuing national and regional patent protection while expanding investments in nanotechnology-based product development. The company says the technology will be used with its European GMP/EMA-certified manufacturing to target next‑generation pharmaceutical, nutraceutical, OTC and specialized healthcare products, but the asset is a pending application with no grant, efficacy data or commercialization timeline disclosed.
COSM: Subsidiary acquires international patent application, expands nanotech R&D
Cosmos Health (NASDAQ: COSM) said its wholly owned Cana Laboratories acquired international patent application WO2025108566A1 from Cloudpharm P.C. and has begun pursuing national and regional patent protection in key markets. The company plans to leverage the patented technology and expanded nanotechnology investments alongside Cana's European GMP/EMA‑certified manufacturing to support next‑generation pharmaceutical, nutraceutical and OTC product development, though the application is not yet a granted patent and no financial or timeline details were disclosed.
COSM launches Oliv18 olive polyphenol supplement in U.S., targets cardiovascular & antioxidant markets
Cosmos Health (COSM) launched Oliv18, a USDA- and EU-organic certified, 100% solvent-free whole olive polyphenol supplement in the U.S., standardized to hydroxytyrosol and oleuropein with a 250 mg daily dose that meets EFSA's 5 mg/day hydroxytyrosol threshold for LDL oxidation protection. The product is positioned in the company’s premium 18 Series to target the large and growing cardiovascular and antioxidant supplement markets (combined global market projection cited >$33B by 2035).
COSM: Sky Premium Life now shippable to all 27 EU member states via Skroutz
Cosmos Health (COSM) announced its Sky Premium Life brand is now available for shipment across all 27 EU member states through the Skroutz e‑commerce platform, with 96 Sky Premium Life products listed. The move expands the brand's pan‑European reach via Skroutz's cross‑border logistics and could increase visibility and potential sales, though no financial terms, sales guidance, or timelines were disclosed.
COSM: Cosmos Health flags ~$20M in non-core assets (real estate ~$15M) for monetization
Cosmos Health (NASDAQ: COSM) said it has identified roughly $20 million of non-core assets — primarily real estate (~$15M, largely unencumbered), plus digital assets and marketable securities — that could be sold, sale‑and‑leasebacked, or borrowed against to generate liquidity without hurting core operations. Management says proceeds could fund a meaningful acquisition or eliminate net debt, but the plan is exploratory with no definitive transactions or timeline and depends on market conditions.
COSM expands C-Scrub into veterinary market after passing EN 1656/1657 tests
Cosmos Health (NASDAQ: COSM) said it will extend its C‑Scrub Wash 4% into the veterinary/animal health market, launching first in the UK and planning wider international expansion into a market estimated at ~$68.7B in 2025. Independent EN 1656 (bactericidal) and EN 1657 (yeasticidal) lab testing showed required log reductions versus key reference organisms at undiluted (80%) and 50% concentrations with a 10‑minute contact time, supporting commercial use in veterinary settings but stopping short of regulatory approvals.